Drugs / NRG-103
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06757153 | Dec 2024 → Aug 2027 expected | glioblastoma | Zhongnan Hospital | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07710690 | Jul 2026 → Apr 2030 expected | malignant glioma | Neuregen Therapeutics Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NRG-103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07710690 ↗ |